Multi‐institutional experience with COVID‐19 convalescent plasma in children

• DOI: 10.1111/trf.17318
• Publication Date: 2023-03-25T20:07:28Z
• Authors: Cyril Jacquot; Oren Gordon; Daniel Noland; Jeffrey R. Donowitz; Emily Levy; Sanjay Jain; Zachary Willis; Casey Rimland; Michele Loi; Antonio Arrieta; Kyle Annen; Noelle Drapeau; Stephanie Osborne; Monica I. Ardura; Satyam Arora; Elise Zivick; Meghan Delaney
• Keywords: Convalescent plasma; 2019-20 coronavirus outbreak; Betacoronavirus; Convalescence; Coronavirus Infections

Convalescent COVID-19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity. Adult studies suggest administering high-titer CCP early in the disease course of patients who are expected to be antibody-negative; however, pediatric experience is limited. We created multi-institutional registry characterize (<18 years) received assess safety this intervention.